In a nutshell The study compared the effectiveness of darolutamide (Nubeqa), apalutamide (Erleada), and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that darolutamide, apalutamide, and enzalutamide were similarly effective and improved survival outcomes compared to placebo...
Read More
In a nutshell This study evaluated the effectiveness of fulvestrant (Faslodex) plus capivasertib (AZD5363) in patients with aromatase inhibitor-resistant estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that fulvestrant plus capivasertib significantly improved the survival outcomes in these...
Read More
In a nutshell The study compared the effectiveness and safety outcomes of androgen-deprivation therapy (ADT) with either apalutamide (Erleada) or darolutamide (Nubeqa) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC). The data showed that apalutamide plus ADT was safe and more effective in improving...
Read More
In a nutshell This study evaluated the effectiveness of radiotherapy (RT) plus androgen receptor-targeted therapy (ARTT) on oligo-progressive sites for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that RT on oligo-progressive sites was safe and effective in prolonging treatment with ARTT in...
Read More
In a nutshell This study evaluated the effectiveness and safety of apalutamide (Erleada) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that apalutamide plus AAP combination significantly improved...
Read More
In a nutshell This study compared the effectiveness and safety of extended therapy with letrozole (LET; Femara) for 5 years versus the standard therapy of 2-3 years for the treatment of postmenopausal women with early-stage breast cancer (BC). The data showed that extended treatment with LET for 5 years significantly improved the survival outcomes...
Read More
In a nutshell This study evaluated the effectiveness and safety outcomes of ipatasertib (GDC-0068) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that ipatasertib plus...
Read More
In a nutshell This study analyzed the effectiveness and safety of new hormonal therapies (nHTs) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The authors concluded that nHT improved the outcomes of these patients. Some background CRPC is an aggressive type of prostate cancer that is resistant to androgen...
Read More
In a nutshell This study compared the real-world outcomes of two widely used drugs, abiraterone (Zytiga) and enzalutamide (Xtandi) in patients diagnosed with metastatic castrate-resistant prostate cancer (mCRPC). The study showed that both drugs were effective in these patients in a real-world setting, with better results...
Read More
In a nutshell The study compared the effectiveness and safety outcomes of darolutamide (Nubeqa) with apalutamide (Erleada) and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (CRPC). The data showed that darolutamide was safer and had similar effectiveness compared to apalutamide and enzalutamide. Some background...
Read More
In a nutshell This study evaluated the effectiveness of salvage radiotherapy (RT) in patients with recurrence of prostate cancer (PCa) after prostate surgery. The study found that salvage RT was effective in the management of PCa recurrence with manageable side effects. Some background Localized prostate cancer (PCa) is a form of cancer that...
Read More
In a nutshell This study reviewed the effectiveness and safety of lutetium-177 [177Lu]-prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that PRLT was associated with good outcomes and manageable side effects. Some...
Read More
